Freya Biosciences, a biotech company focused on women’s health, has secured a $10.4 million strategic investment from the Bill & Melinda Gates Foundation, along with $1.4 million additional financing from EIFO (Export and Investment Fund of Denmark). The funding extends the company’s Series A to approximately $50 million. The investment will support the expansion of Freya’s DYSCOVERTM platform to develop microbial immunotherapies…
Parallel Fluidics, a company developing on-demand microfluidic manufacturing solutions with applications in IVF and other life science fields, has secured $7 million in seed funding. The round was led by J2 Ventures with participation from 8VC and Praxis. The company’s technology is already making waves in the fertility sector. Overture Life, a startup focused on simplifying IVF procedures, is utilizing Parallel Fluidics’…
Rallybio has received approval to begin testing a preventive treatment for a rare but serious pregnancy complication that affects mothers and their unborn babies. The condition, known as fetal and neonatal alloimmune thrombocytopenia (FNAIT), occurs when a pregnant woman’s immune system attacks her baby’s platelets, potentially causing dangerous bleeding in the fetus or newborn. The company will begin Phase 2 clinical trials…
Cartherics, an Australian biotech company developing immune cell therapies, has announced the successful completion of an oversubscribed private financing round, raising over AU$15 million. This funding will primarily support the clinical trial of CTH-401, the company’s lead cell therapy for ovarian cancer, and expand its pipeline to include other diseases. Based in Melbourne, Cartherics focuses on developing cell-based immunotherapies for cancer treatment.…
Helaina, a biotechnology company focused on human equivalent bioactive proteins, has announced a $45 million Series B funding round bringing the company’s total equity funding to $83 million. Avidity Partners led the round, with participation from Spark Capital, Ingeborg Investments, Tom Williams of Heron Rock, Barrel Ventures, Siam Capital, Relish Works, CF Private Equity, and Primary Venture Partners, among others. The funding…
U-Ploid, a venture-backed biotech company, has introduced its new platform designed to enhance the quality of older egg cells, a critical factor in increasing the success rates of in vitro fertilization (IVF) for women experiencing age-related infertility. The company’s technology aims to repair decades of accumulated damage in eggs, thereby improving their viability during IVF treatments. Age-related fertility decline affects millions worldwide,…
BoobyBiome, a biotechnology company focused on infant health, has secured a £1.6 million Biomedical Catalyst grant from Innovate UK. The funding will support the testing and scale-up of BoobyBiome’s Synbiotic, a product developed from breast milk to improve gut health in infants. “We are delighted to receive this substantial grant from Innovate UK,” stated Dr. Lydia Mapstone, CEO and Co-founder of BoobyBiome.…
DiaMedica Therapeutics, a clinical-stage biopharmaceutical company focused on novel treatments for severe ischemic diseases, has announced the initiation of a Phase 2 trial for their preeclampsia treatment, DM199. This announcement came alongside their second quarter 2024 financial results and business update. Preeclampsia (PE) is a serious pregnancy complication characterized by high blood pressure and damage to organ systems, often affecting the kidneys…
